Bibliographic information

GuidelineWHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of human papillomavirus (HPV) DNA genotyping
Year of Publication2026
Issuing InstitutionWorld Health Organization

Recommendation

New

(Screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of human papillomavirus (HPV) DNA genotyping) Recommendations for the general population of women. Regardless of follow-up capacity If a programme provides triage with additional tests, WHO suggests using visual inspection with acetic acid (VIA) or colposcopic impression (without histological confirmation) as the triage test rather than cytology or dual-stain cytology.

Recommended in favor

Conditional

Notes and Remarks

The choice of triage test will depend on availability, installed capacity, feasibility, training and programme quality assurance in countries. To determine treatment type, women should first undergo visual evaluation for eligibility for ablative treatment. Women who are not eligible for ablative treatment should be treated using large-loop excision of the transformation zone (LLETZ) or referred for further management if cancer is suspected.